Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia.

Acta biomaterialia - 15 Oct 2024

Ansari Aysha S, Kucharski Cezary, Kc Remant, Nisakar Daniel, Rahim Ramea, Jiang Xiaoyan, Brandwein Joseph, Uludağ Hasan

Abstract excerpt

Approximately 25% of newly diagnosed AML patients display an internal tandem duplication (ITD) in the fms-like tyrosine kinase 3 (FLT3) gene. Although both multi-targeted and FLT3 specific tyrosine kinase inhibitors (TKIs) are being utilized for clinical therapy, drug resistance, short remission periods, and high relapse rates are challenges that still need to be tackled. RNA interference (RNAi), mediated by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Polymers

Share to Pyrazines

Share to RNA, Small Interfering

Source

Identifiers

PMID: 39236794
DOI: 10.1016/j.actbio.2024.08.053

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia.PMID 39236794Read ↗

Lipopolymer Mediated siRNA Delivery Targeting Aberrant Oncogenes for Effective Therapy of Myeloid LeukemiaSemantic proximity Read ↗

Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles.Semantic proximity Read ↗

Anti-FLT3 nanoparticles for acute myeloid leukemia: Preclinical pharmacology and pharmacokinetics.Semantic proximity Read ↗

Nanoparticle-mediated Targeting of the Fusion Gene <i>RUNX1/ETO</i> in t(8;21)-positive Acute Myeloid LeukaemiaSemantic proximity Read ↗

Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemiaSemantic proximity Read ↗

Antisense oligonucleotides as a targeted therapeutic approach in model of acute myeloid leukemiaSemantic proximity Read ↗

Targeting the 3’ splice site by a decoy oligonucleotide attenuates U2AF1 splicing activity and inhibits leukemiaSemantic proximity Read ↗

Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes.Semantic proximity Read ↗

Induced Apoptosis Investigation in Wild-type and FLT3-ITD Acute Myeloid Leukemia Cells by Nanochannel Electroporation and Single-cell qRT-PCR.Semantic proximity Read ↗

Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer—Drug Carriers MatterSemantic proximity Read ↗

Ribonucleotide Reductase Inhibition Overcomes FLT3 Inhibitor Resistance in Acute Myeloid LeukemiaSemantic proximity Read ↗

siRNA Mediated Genetic Perturbation of Primary Human Leukemia Stem and Progenitor CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.